Home
Company
Therapeutic Focus
Pipeline
UNI-494
Renazorb
Investors
Resources
Contact
All SEC Filings
Investors
Investors
Overview
News
Events & Presentations
IR Calendar
Presentations
Governance
Overview
Management Team
Board of Directors
Board Committees
Governance Documents
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Financial & Stock Info
Overview
Financial Results
Quote
Charts
Historical Data
Analyst Coverage
Resources
Overview
Contacts
FAQ
Email Alerts
Filing Type:
View All
10-K
10-Q
3
4
4/A
424B3
424B4
8-A12B
8-K
ARS
CERT
CORRESP
D
DEF 14A
DEFA14A
DRS
DRS/A
DRSLTR
EFFECT
NT 10-Q
PRE 14A
S-1
S-1/A
S-3
S-8
SC 13G
SC 13G/A
SEC STAFF LETTER
UPLOAD
Year:
View All
2024
2023
2022
2021
2020
2019
Date
Form
Description
PDF
XBRL
Pages
09/15/20
DRS
Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
121
06/03/20
D
Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(a)(5) under the Act.
5
08/16/19
D
Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(a)(5) under the Act.
5
03/04/19
D
Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(a)(5) under the Act.
5
rss_feed
Filing RSS
arrow_back
1…
10
11
12
13
14
15
16
17
18
19
Email Alerts
Contacts
RSS News Feed